rectification and modification of schedules

Schedule XLII - Israel

The following communication, dated 14 January 2019, is being circulated at the request of the delegation of Israel.

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

Israel hereby submits a draft rectification to Schedule XLII - Israel pursuant to the Procedures for Modification and Rectification of Schedules of Tariff Concessions[[1]](#footnote-1). This communication seeks to correct an error in Israel's HS2012 transposition.

In this regard, it should be noted that the certification in document WT/Let/1367 did not reflect the correct concession information for HS2012 subheading 3002.10. According to the amendment to the notes on methodology for the HS2012 transposition (G/MA/330/Add.1), HS2012 subheading 3002.10 should retain the concessions related to the HS2007 subheading 3002.10. Detailed explanatory notes are contained in Attachment 12. The proposed rectification to correct this error is contained in Attachment 2 to this communication.[[2]](#footnote-2)

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

If no objection is notified to the Secretariat within three months from the date of this document, the rectifications and modifications to Schedule XLII - Israel will be deemed to be approved and will be formally certified.

ATTACHMENT 1 – EXPLANATORY NOTE

According to the methodology followed by the Secretariat in document G/MA/330, a simplification should be used for the transposition of HS2012 subheading 3002.10. Further to comments from other Members, an amendment to the simplification of this subheading was adopted by the Committee on Market Access in G/MA/330/Add.1. In this document, the Secretariat suggested for HS2012 subheading 3002.10 to retain the concessions related to the HS2007 subheading 3002.10 instead of using the mode of the candidate lines. This amendment was not reflected in Israel's HS2012 transposition certified in WT/Let/1367. As a result, the following correction is required to reflect the amendment:

| **WT/Let/1367** |  | **Proposed Rectification** |
| --- | --- | --- |
| **Existing HS2012 code** | **Existing Product Description** | **Existing FinalBound Rate** |  | **Proposed HS2012 code** | **Proposed Product Description** | **Proposed Final****Bound Rate** |
| 30021000 | - Antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes | 5 |  | **300210** | - Antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes |  |
|  | **30021010** | **- - Tetanus immune globine human** | **8** |
|  | **30021090** | **- - Other** | **5** |

**\*Bold represents the revision**

**ATTACHMENT 2 – DRAFT RECTIFICATION**

**SCHEDULE XLII - ISRAEL**

**PART I - MOST-FAVOURED NATION TARIFF**

**SECTION II – Other Products**

| **Tariff item(HS2012)** | **Description of Products** | **Base rate of duty** | **Bound rate of duty** | **Implementation period from/to (\*)** | **Initial Negotiating Right** | **Other duties and charges** |
| --- | --- | --- | --- | --- | --- | --- |
| 300210 | - Antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes |  |  |  |  |  |
| 30021010 | - - Tetanus immune globine human |  | 8 |  |  | 0 |
| 30021090 | - - Other |  | 5 |  |  | 0 |

**\_\_\_\_\_\_\_\_\_\_**

1. Decision of 26 March 1980, GATT BISD 27S/25. [↑](#footnote-ref-1)
2. In English only. [↑](#footnote-ref-2)